β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients
Journal of Antimicrobial Chemotherapy · 01.12.2023 · 78 (12) · 2816-2823
DOI: 10.1093/jac/dkad301 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.10.2023. Verfasst von Alexandra Greco Kinney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, WVU Medicine, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Pneumonia, Community-Acquired Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
Community-acquired pneumonia (CAP) is a significant source of hospital admissions and mortality. Atypical organisms are implicated in up to 40% of cases of CAP diagnoses. We studied the difference in outcomes of severe CAP patients treated with doxycycline versus azithromycin in addition to β-lactam therapy. Patients and methods This was a prospective observational cohort study from March 2020 to July 2022 in a medical ICU (MICU) of an academic quaternary medical center. Adults ≥18 years admitted to the MICU receiving doxycycline or azithromycin in addition to β-lactam therapy for the treatment of CAP were included for analysis. The primary outcomes were in-hospital and 30 day mortality. Secondary outcomes were ICU and hospital length-of-stay, 30 day readmission, days of mechanical ventilation, escalation and duration of antibiotics, adverse effects such as Clostridioides difficile infection and QTc prolongation.
Results
Sixty-three patients were in the azithromycin group and eighty-six patients in the doxycycline group. Both groups had similar APACHE IV and CURB-65 scores. The mean Charlson Comorbidity Index score was higher for the doxycycline group compared with the azithromycin group (P = 0.04). There was no statistically significant difference in in-hospital and 30 day mortality between the groups (P = 0.53, P = 0.57). There were no significant differences in any of the secondary outcomes.
Conclusions
MICU patients with severe CAP who received doxycycline versus azithromycin in addition to β-lactam treatment showed no significant differences in outcomes. These data offer support for inclusion of doxycycline as an alternative regimen in current IDSA recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, WVU Medicine, Morgantown, WV, USA.
- Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA.
- Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Epidemiology and Biostatistics, West Virginia University, Morgantown, WV, USA.
Zitieren
APA
Greco Kinney, A., Kovacic Scherrer, N., Sarkar, S., Jain, P., Wen, S., & Hadique, S. (2023). β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients. Journal of Antimicrobial Chemotherapy, 78(12), 2816-2823. https://doi.org/10.1093/jac/dkad301
Vancouver
Greco Kinney A, Kovacic Scherrer N, Sarkar S, Jain P, Wen S, Hadique S. β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients. Journal of Antimicrobial Chemotherapy. 2023;78(12):2816-2823. doi:10.1093/jac/dkad301
BibTeX
@article{GrecoKinney2023,
author = {Greco Kinney, Alexandra and Kovacic Scherrer, Nicole and Sarkar, Sauradeep and Jain, Pranav and Wen, Sijin and Hadique, Sarah},
title = {β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {12},
pages = {2816--2823},
doi = {10.1093/jac/dkad301}
}
EUVIMED